$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024035225 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$13.54M	$20.10M
YoY Change	4.15%	51.79%
Cost Of Revenue	$4.437M	$4.526M
YoY Change	-7.52%	-31.6%
Gross Profit	$9.105M	$15.57M
YoY Change	10.98%	135.1%
Gross Profit Margin	67.24%	77.48%
Selling, General & Admin	$12.13M	$11.36M
YoY Change	64.2%	54.29%
% of Gross Profit	133.18%	72.92%
Research & Development	$5.269M	$4.162M
YoY Change	64.86%	19.84%
% of Gross Profit	57.87%	26.73%
Depreciation & Amortization	$159.0K	$165.0K
YoY Change	-27.06%	-34.0%
% of Gross Profit	1.75%	1.06%
Operating Expenses	$17.40M	$15.52M
YoY Change	64.4%	43.25%
Operating Profit	-$8.290M	$55.00K
YoY Change	248.76%	-101.31%
Interest Expense	-$1.801M	$2.779M
YoY Change	-243.39%	102.4%
% of Operating Profit		5052.73%
Other Income/Expense, Net	-$1.418M	-$1.416M
YoY Change
Pretax Income	-$11.51M	-$2.745M
YoY Change	429.15%	-50.16%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.51M	-$2.745M
YoY Change	465.55%	-52.61%
Net Earnings / Revenue	-84.99%	-13.66%
Basic Earnings Per Share	-$0.13	-$0.03
Diluted Earnings Per Share	-$0.13	-$0.03
COMMON SHARES
Basic Shares Outstanding	91.06M shares	91.04M shares
Diluted Shares Outstanding	91.08M shares	90.91M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.89M	$89.87M
YoY Change	212.57%	300.56%
Cash & Equivalents	$77.89M	$89.87M
Short-Term Investments
Other Short-Term Assets	$1.972M	$1.177M
YoY Change	3.25%	-9.53%
Inventory	$7.021M	$6.966M
Prepaid Expenses
Receivables	$9.684M	$5.998M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$96.57M	$104.0M
YoY Change	127.45%	161.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.848M	$3.921M
YoY Change	-15.45%	-14.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.230M	$4.238M
YoY Change	-22.44%	-22.51%
Total Long-Term Assets	$13.39M	$13.59M
YoY Change	-21.21%	-20.99%
TOTAL ASSETS
Total Short-Term Assets	$96.57M	$104.0M
Total Long-Term Assets	$13.39M	$13.59M
Total Assets	$110.0M	$117.6M
YoY Change	84.97%	106.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.572M	$5.696M
YoY Change	-24.23%	-46.71%
Accrued Expenses	$5.025M	$5.674M
YoY Change	-8.1%	33.1%
Deferred Revenue	$1.048M	$1.046M
YoY Change	-60.26%	-73.8%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$25.00K	$24.00K
YoY Change	-99.46%	-99.87%
Total Short-Term Liabilities	$15.15M	$13.90M
YoY Change	-37.02%	-64.05%
LONG-TERM LIABILITIES
Long-Term Debt	$31.25M	$30.01M
YoY Change	-9.57%	44.25%
Other Long-Term Liabilities	$2.033M	$2.027M
YoY Change	1.09%	1.05%
Total Long-Term Liabilities	$2.033M	$2.027M
YoY Change	1.09%	1.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.15M	$13.90M
Total Long-Term Liabilities	$2.033M	$2.027M
Total Liabilities	$155.4M	$153.1M
YoY Change	-4.31%	-6.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$346.2M	-$334.7M
YoY Change	11.32%	8.33%
Common Stock	$91.00K	$91.00K
YoY Change	35.82%	46.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$45.42M	-$35.48M
YoY Change
Total Liabilities & Shareholders Equity	$110.0M	$117.6M
YoY Change	84.97%	106.35%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$11.51M	-$2.745M
YoY Change	465.55%	-52.61%
Depreciation, Depletion And Amortization	$159.0K	$165.0K
YoY Change	-27.06%	-34.0%
Cash From Operating Activities	-$11.88M	-$7.006M
YoY Change	405.53%	-11.39%
INVESTING ACTIVITIES
Capital Expenditures	$80.00K	$35.00K
YoY Change	-46.67%	-95.76%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.00K	-$35.00K
YoY Change	-46.67%	-95.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-17.00K	1.711M
YoY Change	-100.34%	-60.09%
NET CHANGE
Cash From Operating Activities	-11.88M	-7.006M
Cash From Investing Activities	-80.00K	-35.00K
Cash From Financing Activities	-17.00K	1.711M
Net Change In Cash	-11.98M	-5.330M
YoY Change	-582.94%	19.88%
FREE CASH FLOW
Cash From Operating Activities	-$11.88M	-$7.006M
Capital Expenditures	$80.00K	$35.00K
Free Cash Flow	-$11.96M	-$7.041M
YoY Change	378.4%	-19.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Interest Expense InterestExpense	2779000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1373000	usd
	us-gaap	Interest Expense InterestExpense	5563000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13241000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20099000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13241000	usd
CY2024Q2	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	5998000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3119000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82263168	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68533085	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68533085	shares
	us-gaap	Interest Expense InterestExpense	2808000	usd
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	116000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-118554000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	993000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	77000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	344000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-8000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	8068000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-109235000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4409000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	235000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	31000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	631000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-3000	usd
CY2023Q2	us-gaap	Stockholders Equity Other StockholdersEquityOther	-1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5792000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-106651000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15573000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2276000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	412000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	614000	usd
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	300000	usd
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3119000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	975000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5342000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	115000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-19000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	267000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2486000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4728000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	197000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	170000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1871000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1812000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1730000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	743000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1746000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4643000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-11093000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4182000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17390000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	909000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	828000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-828000	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	0	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	3542000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	30000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	31000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	539000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	10000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	12543000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1027000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	898000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83452000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4918000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	65998000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4837000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23872000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27273000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89870000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22436000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	305000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	2528000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2820000	usd
	aqst	Revenue From Contract With Customer Number Of Commercialized Products RevenueFromContractWithCustomerNumberOfCommercializedProducts	5	product
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89870000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-334650000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	601000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	1662000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	22803000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33896000	usd
CY2024Q2	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	496000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	715000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20099000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32152000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24375000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32152000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24375000	usd
CY2024Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4331000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5570000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1668000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2915000	usd
CY2023Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	8471000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	26000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	3090000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2118000	usd
CY2024Q2	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	2456000	usd
CY2023Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	3028000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1420000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1623000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	6966000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	6769000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47126000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47063000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43205000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42884000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3921000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4179000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	165000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	250000	usd
	us-gaap	Depreciation Depreciation	333000	usd
	us-gaap	Depreciation Depreciation	536000	usd
CY2024Q2	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	444000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	888000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	111000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	226000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	452000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	870000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	121000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	229000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	629000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1284000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1318000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1346000	usd
CY2024Q2	aqst	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	5094000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9671000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3978000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5693000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4367000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4367000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3089000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1278000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	78000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	78000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1500000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1200000	usd
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	300000	usd
CY2024Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	300000	usd
CY2024Q2	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	3000000	usd
CY2023Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	4000000	usd
CY2024Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1238000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1438000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4238000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5438000	usd
CY2024Q2	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	royalty_payment
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2667000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4202000	usd
CY2024Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	382000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	337000	usd
CY2024Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	653000	usd
CY2023Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	645000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	1536000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1013000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	436000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	300000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5674000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6497000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9540000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	14535000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	20925000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	45000000	usd
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5874000	usd
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2023Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64490000	usd
CY2022Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	65259000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	116000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	usd
CY2024Q2	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1000000	usd
CY2023Q4	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	922000	usd
CY2024Q2	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	63684000	usd
CY2023Q2	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	64490000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2745000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5792000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15573000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2276000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90911626	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57350902	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82263168	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56494805	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1910742	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90911626	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57350902	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58938222	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1539000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	648000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	992000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1539000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	648000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3119000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	992000	usd
	aqst	Inducement Equity Common Stock Options Outstanding Shares InducementEquityCommonStockOptionsOutstandingShares	0	shares
CY2023Q4	us-gaap	Share Price SharePrice	2.60
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2745000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15573000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.052
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.111
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	284000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	284000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5508000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2560000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17390000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	909000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-828000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83452000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4918000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	65998000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4837000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
aqst-20240630_cal.xml	Edgar Link	unprocessable
0001628280-24-035225-index-headers.html	Edgar Link	pending
0001628280-24-035225-index.html	Edgar Link	pending
0001628280-24-035225.txt	Edgar Link	pending
0001628280-24-035225-xbrl.zip	Edgar Link	pending
aqst-20240630.htm	Edgar Link	pending
aqst-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
q22024ex311.htm	Edgar Link	pending
q22024ex312.htm	Edgar Link	pending
q22024ex321.htm	Edgar Link	pending
q22024ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
aqst-20240630_def.xml	Edgar Link	unprocessable
aqst-20240630_lab.xml	Edgar Link	unprocessable
aqst-20240630_pre.xml	Edgar Link	unprocessable
aqst-20240630_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2024 Q3 Form 10-Q Financial Statement

#000162828024035225 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2024 Q3 Form 10-Q Financial Statement

#000162828024035225 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst